Goldman Sachs’s TriSalus Life Sciences TLSI Stock Holding History

Goldman Sachs’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$300K	Buy	75,049 +9,081	+14%	+$44.5K	﹤0.01%	5892
2025 Q4	$460K	Sell	65,968 -84,519	-56%	-$473K	﹤0.01%	5641
2025 Q3	$700K	Buy	150,487 +133,671	+795%	+$626K	﹤0.01%	5299
2025 Q2	$91.6K	Sell	16,816 -17,084	-50%	-$91.6K	﹤0.01%	5834
2025 Q1	$187K	Buy	+33,900	New	+$180K	﹤0.01%	5657
2024 Q3	–	Sell	-23,045	Closed	-$127K	–	6069
2024 Q2	$127K	Sell	23,045 -31,430	-58%	-$267K	﹤0.01%	5368
2024 Q1	$531K	Buy	+54,475	New	+$503K	﹤0.01%	4721
2022 Q4	–	Sell	-135,789	Closed	-$1.35M	–	6268
2022 Q3	$1.35M	Sell	135,789 -305,570	-69%	-$3.02M	﹤0.01%	4315
2022 Q2	$4.34M	Buy	441,359 +50,500	+13%	+$496K	﹤0.01%	3268
2022 Q1	$3.83M	Buy	390,859 +255,279	+188%	+$2.52M	﹤0.01%	3611
2021 Q4	$1.34M	Hold	135,580	–	–	﹤0.01%	4599
2021 Q3	$1.35M	Sell	135,580 -37,100	-21%	-$363K	﹤0.01%	4523
2021 Q2	$1.68M	Buy	172,680 +14,980	+9%	+$147K	﹤0.01%	4360
2021 Q1	$1.52M	Buy	+157,700	New	+$1.6M	﹤0.01%	4261

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.7B AUM 6.69% 1-Year Est. Return

Goldman Sachs's TLSI Position: Q1 2026 in Review

Goldman Sachs increased its TriSalus Life Sciences (TLSI) stake by 14% in Q1 2026, buying an estimated $44.5K and bringing the position to 75,049 shares worth $300K. The position accounts for ﹤0.01% of the portfolio, ranked #5892.

Goldman Sachs first reported a position in TLSI in Q1 2021 and has held it in 14 quarters since. The position peaked at $4.34M in Q2 2022. 84 funds tracked by Wall St. Rank hold TLSI as of Q1 2026.

Goldman Sachs held 75,049 shares of TriSalus Life Sciences worth $300K as of Q1 2026.
Goldman Sachs bought 9,081 TriSalus Life Sciences shares in Q1 2026, an estimated $44.5K.
TriSalus Life Sciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5892 holding.
Goldman Sachs first reported a position in TriSalus Life Sciences in Q1 2021 and has held it in 14 quarters since.
Goldman Sachs's TriSalus Life Sciences position peaked at $4.34M in Q2 2022.
84 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.